-

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2023

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2023 of $1.19 per share on the company’s common stock. The dividend is payable on September 7, 2023 to shareholders of record at the close of business on August 28, 2023. The ex-dividend date is August 25, 2023.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Contacts

Press Contact:
Tesia Williams
media-relations@its.jnj.com

Investor Contact:
Jessica Moore
investor-relations@its.jnj.com

Industry:

Johnson & Johnson

Release Versions
English

Contacts

Press Contact:
Tesia Williams
media-relations@its.jnj.com

Investor Contact:
Jessica Moore
investor-relations@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs and impact investments that empower health workers to deliver cardiac, vision and surgical care in their communiti...

Johnson & Johnson reports Q4 and Full-Year 2025 results

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros...

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1. “Today’s agreement shows that when...
Back to Newsroom